RepurpOS

Sarcopenia

Disease intelligence for Sarcopenia: 130 alterations and 82 ranked therapeutics from curated public databases.

US DALYs4.08MWHO GHE 2021 · all ages
Global DALYs45.69MWHO GHE 2021 · worldwide
US mortality12.5K deaths/yrWHO GHE 2021
Global mortality110.0K deaths/yrWHO GHE 2021 · worldwide
NIH funding$37MFY2025 · RCDC estimate
Funding levelSeverely Underfunded

Disease overview

Alterations
130
Molecular (A)
100
Clinical (B–E)
0
Trial outcome measures (T)
30
Direct drugs
23
Via biomarker
52
Natural agents
8
Natural products
73
Merged ranked
82
With trial/literature evidence
25

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, OSMF Chronic Disease Review, PubMed MeSH, PubMed Literature · Pipeline phase 7 · Updated 2026-10-15

Related: Fitness landscape

Identifiers: EFO: EFO_1000653 · MESH: D055948

Alterations

130 total · Types A (molecular) through E (functional). Molecular rows are Open Targets gene–disease associations (evidence column = OT association score), not measured levels; phenotypes are HPO terms annotated directly to this disease (Monarch); type T rows are outcome measures used in completed ClinicalTrials.gov studies, not alterations of the disease.

NameTypeSubtypeDirection FrequencyEvidenceSourcesLinks
FTO
FTO alpha-ketoglutarate dependent dioxygenase
 Molecular Gene — — OT score 0.38 Open Targets UniProt Ensembl Open Targets
TNFSF11
TNF superfamily member 11
 Molecular Gene — — OT score 0.33 Open Targets UniProt Ensembl Open Targets
NDUFC1
NADH:ubiquinone oxidoreductase subunit C1
 Molecular Gene — — OT score 0.27 Open Targets UniProt Ensembl Open Targets
NDUFS8
NADH:ubiquinone oxidoreductase core subunit S8
 Molecular Gene — — OT score 0.27 Open Targets UniProt Ensembl Open Targets
NDUFB5
NADH:ubiquinone oxidoreductase subunit B5
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFS1
NADH:ubiquinone oxidoreductase core subunit S1
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFS3
NADH:ubiquinone oxidoreductase core subunit S3
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
COXFA4
cytochrome c oxidase associated subunit FA4
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
COXFA4L2
cytochrome c oxidase hypoxia associated subunit FA4L2
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
GPD2
glycerol-3-phosphate dehydrogenase 2
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
MT-ND1
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
MT-ND2
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
MT-ND3
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
MT-ND4
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
MT-ND4L
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
MT-ND5
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
MT-ND6
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA1
NADH:ubiquinone oxidoreductase subunit A1
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA10
NADH:ubiquinone oxidoreductase subunit A10
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA11
NADH:ubiquinone oxidoreductase subunit A11
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA12
NADH:ubiquinone oxidoreductase subunit A12
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA13
NADH:ubiquinone oxidoreductase subunit A13
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA2
NADH:ubiquinone oxidoreductase subunit A2
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA3
NADH:ubiquinone oxidoreductase subunit A3
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA5
NADH:ubiquinone oxidoreductase subunit A5
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA6
NADH:ubiquinone oxidoreductase subunit A6
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA7
NADH:ubiquinone oxidoreductase subunit A7
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA8
NADH:ubiquinone oxidoreductase subunit A8
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFA9
NADH:ubiquinone oxidoreductase subunit A9
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFAB1
NADH:ubiquinone oxidoreductase subunit AB1
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFAF1
NADH:ubiquinone oxidoreductase complex assembly factor 1
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFAF2
NADH:ubiquinone oxidoreductase complex assembly factor 2
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFAF3
NADH:ubiquinone oxidoreductase complex assembly factor 3
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFAF4
NADH:ubiquinone oxidoreductase complex assembly factor 4
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFB1
NADH:ubiquinone oxidoreductase subunit B1
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFB10
NADH:ubiquinone oxidoreductase subunit B10
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFB11
NADH:ubiquinone oxidoreductase subunit B11
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFB2
NADH:ubiquinone oxidoreductase subunit B2
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFB3
NADH:ubiquinone oxidoreductase subunit B3
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFB4
NADH:ubiquinone oxidoreductase subunit B4
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFB6
NADH:ubiquinone oxidoreductase subunit B6
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFB7
NADH:ubiquinone oxidoreductase subunit B7
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFB8
NADH:ubiquinone oxidoreductase subunit B8
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFB9
NADH:ubiquinone oxidoreductase subunit B9
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFC2
NADH:ubiquinone oxidoreductase subunit C2
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFS2
NADH:ubiquinone oxidoreductase core subunit S2
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFS4
NADH:ubiquinone oxidoreductase subunit S4
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFS5
NADH:ubiquinone oxidoreductase subunit S5
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFS6
NADH:ubiquinone oxidoreductase subunit S6
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFS7
NADH:ubiquinone oxidoreductase core subunit S7
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFV1
NADH:ubiquinone oxidoreductase core subunit V1
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFV2
NADH:ubiquinone oxidoreductase core subunit V2
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
NDUFV3
NADH:ubiquinone oxidoreductase subunit V3
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
FDPS
farnesyl diphosphate synthase
 Molecular Gene — — OT score 0.26 Open Targets UniProt Ensembl Open Targets
GHR
growth hormone receptor
 Molecular Gene — — OT score 0.21 Open Targets UniProt Ensembl Open Targets
MSTN
myostatin
 Molecular Gene — — OT score 0.13 Open Targets UniProt Ensembl Open Targets
FNDC5
fibronectin type III domain containing 5
 Molecular Gene — — OT score 0.11 Open Targets UniProt Ensembl Open Targets
CRP
C-reactive protein
 Molecular Gene — — OT score 0.11 Open Targets UniProt Ensembl Open Targets
IL6
interleukin 6
 Molecular Gene — — OT score 0.11 Open Targets UniProt Ensembl Open Targets
IGF1
insulin like growth factor 1
 Molecular Gene — — OT score 0.11 Open Targets UniProt Ensembl Open Targets
GPT
glutamic--pyruvic transaminase
 Molecular Gene — — OT score 0.11 Open Targets UniProt Ensembl Open Targets
GDF15
growth differentiation factor 15
 Molecular Gene — — OT score 0.11 Open Targets UniProt Ensembl Open Targets
INS
insulin
 Molecular Gene — — OT score 0.11 Open Targets UniProt Ensembl Open Targets
ACVR2B
activin A receptor type 2B
 Molecular Gene — — OT score 0.11 Open Targets UniProt Ensembl Open Targets
TNF
tumor necrosis factor
 Molecular Gene — — OT score 0.11 Open Targets UniProt Ensembl Open Targets
AR
androgen receptor
 Molecular Gene — — OT score 0.11 Open Targets UniProt Ensembl Open Targets
IL16
interleukin 16
 Molecular Gene — — OT score 0.10 Open Targets UniProt Ensembl Open Targets
NEFL
neurofilament light chain
 Molecular Gene — — OT score 0.10 Open Targets UniProt Ensembl Open Targets
IL10
interleukin 10
 Molecular Gene — — OT score 0.10 Open Targets UniProt Ensembl Open Targets
PTH
parathyroid hormone
 Molecular Gene — — OT score 0.10 Open Targets UniProt Ensembl Open Targets
SOST
sclerostin
 Molecular Gene — — OT score 0.10 Open Targets UniProt Ensembl Open Targets
SIRT1
sirtuin 1
 Molecular Gene — — OT score 0.09 Open Targets UniProt Ensembl Open Targets
ALB
albumin
 Molecular Gene — — OT score 0.09 Open Targets UniProt Ensembl Open Targets
CST3
cystatin C
 Molecular Gene — — OT score 0.09 Open Targets UniProt Ensembl Open Targets
NPPB
natriuretic peptide B
 Molecular Gene — — OT score 0.09 Open Targets UniProt Ensembl Open Targets
GLP1R
glucagon like peptide 1 receptor
 Molecular Gene — — OT score 0.09 Open Targets UniProt Ensembl Open Targets
ADIPOQ
adiponectin, C1Q and collagen domain containing
 Molecular Gene — — OT score 0.09 Open Targets UniProt Ensembl Open Targets
CXCL10
C-X-C motif chemokine ligand 10
 Molecular Gene — — OT score 0.09 Open Targets UniProt Ensembl Open Targets
CD8A
CD8 subunit alpha
 Molecular Gene — — OT score 0.09 Open Targets UniProt Ensembl Open Targets
APLN
apelin
 Molecular Gene — — OT score 0.09 Open Targets UniProt Ensembl Open Targets
BRD2
bromodomain containing 2
 Molecular Gene — — OT score 0.09 Open Targets UniProt Ensembl Open Targets
TTR
transthyretin
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
LEP
leptin
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
NFE2L2
NFE2 like bZIP transcription factor 2
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
XDH
xanthine dehydrogenase
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
BMP7
bone morphogenetic protein 7
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
AGRN
agrin
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
TTN
titin
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
FGF21
fibroblast growth factor 21
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
ACTN3
actinin alpha 3
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
CD9
CD9 molecule
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
OSTN
osteocrin
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
PRKN
parkin RBR E3 ubiquitin protein ligase
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
FYN
FYN proto-oncogene, Src family tyrosine kinase
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
EGFR
epidermal growth factor receptor
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
CLU
clusterin
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
RETN
resistin
 Molecular Gene — — OT score 0.08 Open Targets UniProt Ensembl Open Targets
GPT2
glutamic--pyruvic transaminase 2
 Molecular Gene — — OT score 0.07 Open Targets UniProt Ensembl Open Targets
DYRK1B
dual specificity tyrosine phosphorylation regulated kinase 1B
 Molecular Gene — — OT score 0.07 Open Targets UniProt Ensembl Open Targets
HSPA12B
heat shock protein family A (Hsp70) member 12B
 Molecular Gene — — OT score 0.07 Open Targets UniProt Ensembl Open Targets
Adherence to PS (BCAA biomarker) Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Assessment of muscle strength and performance. 400-meter Walk Test Perfomance (Day 0 and at 6 weeks of intervention). Trial outcome measure Functional test — — Trial outcome measure ClinicalTrials.gov —
Assessment of muscle strength and performance. Grip strength (Day 0 and at 6 weeks of intervention). Trial outcome measure Functional test — — Trial outcome measure ClinicalTrials.gov —
Assessment of muscle strength and performance. Short Physical Performance Battery (Day 0 and at 6 weeks of intervention). Trial outcome measure Functional test — — Trial outcome measure ClinicalTrials.gov —
Assessment of muscle strength and performance. Timed-up-and-go (Day 0 and at 6 weeks of intervention). Trial outcome measure Functional test — — Trial outcome measure ClinicalTrials.gov —
Based on the results of empirical research on sarcopenia in Asian countries, a diagnostic consensus was established. Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Body composition (Day 0 and at 6 weeks of intervention). Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Calf circumference Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Change in Timed Up and Go Test (TUG) Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Change in muscle mass Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Changes in BMI Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Fat mass Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Fat oxidation (FatMax) during during half-effort test Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Functionality Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Gait speed Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Handgrip strength Trial outcome measure Functional test — — Trial outcome measure ClinicalTrials.gov —
Insulin sensitivity (HOMA-IR) Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov LOINC
Isometric arm flexion strength (Day 0 and at 6 weeks of intervention) Trial outcome measure Functional test — — Trial outcome measure ClinicalTrials.gov —
Metabolic flexibility - oxidation of substrates: VO2 peak Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Muscle mass Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Number of participant deaths Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Nutritional evaluation (Day 0 and at 6 weeks of intervention). Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Physical performance (measured by the Short Physical Performance Battery) Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Quality-of-life change Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Respiratory quotient Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
Strength Trial outcome measure Functional test — — Trial outcome measure ClinicalTrials.gov —
effect of PS and PA on Changes in fat mass and Fat free mass (kg) Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
effect of PS and PA on resting energy expenditure (REE) (Kcal/ day) Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov —
muscle strength Trial outcome measure Functional test — — Trial outcome measure ClinicalTrials.gov —
skeletal muscle mass index Trial outcome measure Clinical scale — — Trial outcome measure ClinicalTrials.gov —

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

From opensourcemed.info/chronic-disease — Reversing decline in aging muscles: expected trends, impacts and remedies. Candidates for further study, not approved treatments.

DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
ACETAZOLAMIDE Repurposing Small molecule Approved Strong 95 UK £3–£8 / 28–56 tabs · US $8–$15 / 30 tabs — ChEMBL ChEMBL Open Targets
AMPHETAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
BICALUTAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CARBACHOL Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL413 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
CIPROFLOXACIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
CLOMIPRAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIAZEPAM Repurposing Small molecule Approved Strong 95 UK £1–£3 / 28 tabs · US $3–$8 / 30 tabs — ChEMBL ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
EPIRUBICIN Repurposing Small molecule Approved Strong 95 Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP) — ChEMBL ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FLUMAZENIL Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
IMIPRAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
INDAPAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
INDOMETHACIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 pubs
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 pubs
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
LUMASIRAN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
MAFENIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
MECAMYLAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METHAZOLAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METHOXSALEN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METOPROLOL Repurposing Small molecule Approved Strong 95 UK £2–£4 / 28 tabs · US $4–$9 / 30 tabs — ChEMBL ChEMBL Open Targets
MIANSERIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NALIDIXIC ACID Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NEDOSIRAN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
NICOTINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
3 pubs
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NORFLOXACIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
OFLOXACIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
PHENYTOIN Repurposing Small molecule Approved Strong 95 UK £3–£8 / supply · US $6–$15 / 30 tabs — ChEMBL ChEMBL Open Targets
PRAZOSIN Repurposing Small molecule Approved Strong 95 UK £2–£6 / 28–60 tabs · US $5–$12 / 30–60 tabs
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
SULBACTAM Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
TAZOBACTAM Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
TROGLITAZONE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL172513 Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DARAPLADIB Repurposing Small molecule Phase III Moderate 70 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FENRETINIDE Repurposing Small molecule Phase III Moderate 70 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1200711 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1200946 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201621 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL191 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL2107910 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL2107951 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL224128 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL283800 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3137353 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3221237 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3545374 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL386630 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ALPRENOLOL Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
AMIFLOXACIN Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
BROLAMFETAMINE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CARZENIDE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIFLOXACIN Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIMECAMINE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ELLAGIC ACID Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ENISOPROST Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FENCAMFAMIN Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FLEROXACIN Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
IDOXIFENE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
LYSERGIDE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
MERAFLOXACIN Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
TENAMFETAMINE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ZIDAPAMIDE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201498 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201631 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL136478 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1536 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL256147 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL291962 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
Dioscorea esculenta (Lesser yam extract) OSMF review Herbal Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Fish oil (Omega-3 fatty acids) OSMF review Supplement Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
8 trials
View evidence

Registry trials

  • NCT04772040 — Impact of Fish Oil Dose on Tissue Content and Function (COMPLETED) NA
  • NCT02617511 — Omega-3 Supplementation and Resistance Training (COMPLETED) NA
  • NCT02103842 — Omega-3 Fatty Acids to Combat Sarcopenia (COMPLETED) PHASE1
  • NCT03462771 — Dietary Supplementation With Omega-3 Fatty Acid in Muscle Response (UNKNOWN) NA
  • NCT05862779 — Effects of Omega-3 and Whey Protein Supplementation on Lean Mass in Older Adults (RECRUITING) NA
  • NCT02779868 — Omega-3 Supplementation in Cervix Cancer Patients Undergoing Chemoradiotherapy (COMPLETED) NA
  • NCT06494566 — Omega-3 Supplementation After Surgical Treatment of Obesity (COMPLETED) EARLY_PHASE1
  • NCT03598413 — PeRioperative Omega Three and the Effect on ImmuNity (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
High-protein diet (>=1.2 g/kg/day) OSMF review Lifestyle Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
5 trials
View evidence

Registry trials

  • NCT03860194 — Effects of Dietary Supplements on Sarcopenic Elders (COMPLETED) NA
  • NCT02379026 — Lifestyle Modifications for the Treatment of Sarcopenic Obesity (UNKNOWN) NA
  • NCT02371278 — Leucine Co-ingestion and Myofibrillar Protein Synthesis in Older Adults (COMPLETED) NA
  • NCT05912309 — Effects of Time-restricted Eating and Exercise Training on Skeletal Muscle Mass Quantity, Quality and Function in Postmenopausal Women With Overweight and Obesity (UNKNOWN) NA
  • NCT03024125 — High vs Normal Protein Diets, Resistance Exercise, Lean Mass and Strength Gains (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Leucine supplementation OSMF review Supplement Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
8 trials 3 Cochrane 2 Meta-analysis 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT03860194 — Effects of Dietary Supplements on Sarcopenic Elders (COMPLETED) NA
  • NCT06971822 — Assessing the Impact of a Leucine Enriched Whey Protein vs Isonitrogenous Whey on Muscle Protein Synthetic Responses in the Rested and Acute Post Exercise States in Older Adults (RECRUITING) NA
  • NCT04309292 — Protein and Skeletal Muscle in Older Twins: Role of the Gut Microbiome (COMPLETED) NA
  • NCT06991855 — Effects of Nutritional Supplementation of Leucine and Polyunsaturated Fatty Acids on Muscle Health in the Elderly (RECRUITING) NA
  • NCT01757340 — Calorie Restriction With Leucine Supplementation (COMPLETED) NA
  • NCT03815201 — Protein Supplementation and Muscle Function in the Elderly (UNKNOWN) NA
  • NCT00807508 — Leucine Supplementation in Elderly Men (COMPLETED) PHASE1, PHASE2
  • NCT06121492 — Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia (ENROLLING_BY_INVITATION) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Losartan OSMF review Small molecule Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT01989793 — A Study of Muscle Strength Maintenance in Older Adults (COMPLETED) PHASE2

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Metformin OSMF review Small molecule Preclinical Emerging 30 UK £1–£3 / 28–56 tabs · US $4–$10 / 30–90 tabs
1 trials 1 Cochrane 1 Meta-analysis 4 Trial pubs 4 RCT
View evidence

Registry trials

  • NCT01804049 — Metformin and Muscle in Insulin-resistant Older Veterans (COMPLETED) PHASE1, PHASE2

Published literature

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Resistance training (Strength training) OSMF review Lifestyle Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
8 trials
View evidence

Registry trials

  • NCT07601321 — BCW-Based Resistance Training for Community-Dwelling Sarcopenia Patients (NOT_YET_RECRUITING) NA
  • NCT05497687 — Strength-building Lifestyle-integrated Intervention (COMPLETED) NA
  • NCT05778136 — Lung Cancer, Exercise and Force Development (UNKNOWN) NA
  • NCT03266575 — Pulmonary Rehabilitation in End-Stage Liver Disease (TERMINATED) NA
  • NCT05194397 — Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors (RECRUITING) PHASE2
  • NCT05691166 — Reducing Falls With Progressive Resistance Training for the Oldest Old Adults With Sarcopenia (ACTIVE_NOT_RECRUITING) NA
  • NCT06480643 — Effect of Exercise Type on Muscle Quality in Patients With OA, SARC and RA: an Explorative Study (NOT_YET_RECRUITING) NA
  • NCT02873676 — Prevalence and Effect of Lifestyle Modification on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Selenium supplementation OSMF review Supplement Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT05324475 — Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition. (RECRUITING) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
ALBUMIN HUMAN Biologic Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — Open Targets ChEMBL Open Targets
CHEMBL2003538 Small molecule Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL454801 Small molecule Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
CHEMBL172513 Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1200711 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1200946 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201621 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL191 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL2107910 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL2107951 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL224128 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL283800 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3137353 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3221237 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3545374 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL386630 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201498 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201631 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL136478 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1536 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL256147 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL291962 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL413 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
ALBUMIN HUMAN Biologic Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — Open Targets ChEMBL Open Targets
CHEMBL2003538 Small molecule Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL454801 Small molecule Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
ACETAZOLAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 UK £3–£8 / 28–56 tabs · US $8–$15 / 30 tabs — ChEMBL ChEMBL Open Targets
AMPHETAMINE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
BICALUTAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CARBACHOL Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CIPROFLOXACIN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIAZEPAM Repurposing via ACTN4 Small molecule Approved Strong 95 UK £1–£3 / 28 tabs · US $3–$8 / 30 tabs — ChEMBL ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
EPIRUBICIN Repurposing via ACTN4 Small molecule Approved Strong 95 Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP) — ChEMBL ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FLUMAZENIL Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
IMIPRAMINE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
INDAPAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
INDOMETHACIN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 pubs
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 pubs
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
LUMASIRAN Repurposing via AGXT Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
MAFENIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
MECAMYLAMINE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METHAZOLAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METHOXSALEN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METOPROLOL Repurposing via ACTN4 Small molecule Approved Strong 95 UK £2–£4 / 28 tabs · US $4–$9 / 30 tabs — ChEMBL ChEMBL Open Targets
MIANSERIN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NALIDIXIC ACID Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NEDOSIRAN Repurposing via AGXT Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
NICOTINE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
3 pubs
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NORFLOXACIN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
OFLOXACIN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
PHENYTOIN Repurposing via ACTN4 Small molecule Approved Strong 95 UK £3–£8 / supply · US $6–$15 / 30 tabs — ChEMBL ChEMBL Open Targets
PRAZOSIN Repurposing via ACTN4 Small molecule Approved Strong 95 UK £2–£6 / 28–60 tabs · US $5–$12 / 30–60 tabs
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
SIROLIMUS Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
SULBACTAM Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
TAZOBACTAM Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
TROGLITAZONE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DARAPLADIB Repurposing via ACTN4 Small molecule Phase III Moderate 70 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FENRETINIDE Repurposing via ACTN4 Small molecule Phase III Moderate 70 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ALPRENOLOL Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
AMIFLOXACIN Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CARZENIDE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIFLOXACIN Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIMECAMINE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ELLAGIC ACID Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ENISOPROST Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FENCAMFAMIN Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FLEROXACIN Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
IDOXIFENE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
LYSERGIDE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
MERAFLOXACIN Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
TENAMFETAMINE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
Dioscorea esculenta (Lesser yam extract) OSMF review Herbal Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Fish oil (Omega-3 fatty acids) OSMF review Supplement Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials
View evidence

Registry trials

  • NCT04772040 — Impact of Fish Oil Dose on Tissue Content and Function (COMPLETED) NA
  • NCT02617511 — Omega-3 Supplementation and Resistance Training (COMPLETED) NA
  • NCT02103842 — Omega-3 Fatty Acids to Combat Sarcopenia (COMPLETED) PHASE1
  • NCT03462771 — Dietary Supplementation With Omega-3 Fatty Acid in Muscle Response (UNKNOWN) NA
  • NCT05862779 — Effects of Omega-3 and Whey Protein Supplementation on Lean Mass in Older Adults (RECRUITING) NA
  • NCT02779868 — Omega-3 Supplementation in Cervix Cancer Patients Undergoing Chemoradiotherapy (COMPLETED) NA
  • NCT06494566 — Omega-3 Supplementation After Surgical Treatment of Obesity (COMPLETED) EARLY_PHASE1
  • NCT03598413 — PeRioperative Omega Three and the Effect on ImmuNity (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
High-protein diet (>=1.2 g/kg/day) OSMF review Lifestyle Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
5 trials
View evidence

Registry trials

  • NCT03860194 — Effects of Dietary Supplements on Sarcopenic Elders (COMPLETED) NA
  • NCT02379026 — Lifestyle Modifications for the Treatment of Sarcopenic Obesity (UNKNOWN) NA
  • NCT02371278 — Leucine Co-ingestion and Myofibrillar Protein Synthesis in Older Adults (COMPLETED) NA
  • NCT05912309 — Effects of Time-restricted Eating and Exercise Training on Skeletal Muscle Mass Quantity, Quality and Function in Postmenopausal Women With Overweight and Obesity (UNKNOWN) NA
  • NCT03024125 — High vs Normal Protein Diets, Resistance Exercise, Lean Mass and Strength Gains (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Leucine supplementation OSMF review Supplement Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 3 Cochrane 2 Meta-analysis 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT03860194 — Effects of Dietary Supplements on Sarcopenic Elders (COMPLETED) NA
  • NCT06971822 — Assessing the Impact of a Leucine Enriched Whey Protein vs Isonitrogenous Whey on Muscle Protein Synthetic Responses in the Rested and Acute Post Exercise States in Older Adults (RECRUITING) NA
  • NCT04309292 — Protein and Skeletal Muscle in Older Twins: Role of the Gut Microbiome (COMPLETED) NA
  • NCT06991855 — Effects of Nutritional Supplementation of Leucine and Polyunsaturated Fatty Acids on Muscle Health in the Elderly (RECRUITING) NA
  • NCT01757340 — Calorie Restriction With Leucine Supplementation (COMPLETED) NA
  • NCT03815201 — Protein Supplementation and Muscle Function in the Elderly (UNKNOWN) NA
  • NCT00807508 — Leucine Supplementation in Elderly Men (COMPLETED) PHASE1, PHASE2
  • NCT06121492 — Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia (ENROLLING_BY_INVITATION) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Losartan OSMF review Small molecule Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT01989793 — A Study of Muscle Strength Maintenance in Older Adults (COMPLETED) PHASE2

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Metformin OSMF review Small molecule Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials 1 Cochrane 1 Meta-analysis 4 Trial pubs 4 RCT
View evidence

Registry trials

  • NCT01804049 — Metformin and Muscle in Insulin-resistant Older Veterans (COMPLETED) PHASE1, PHASE2

Published literature

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Resistance training (Strength training) OSMF review Lifestyle Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials
View evidence

Registry trials

  • NCT07601321 — BCW-Based Resistance Training for Community-Dwelling Sarcopenia Patients (NOT_YET_RECRUITING) NA
  • NCT05497687 — Strength-building Lifestyle-integrated Intervention (COMPLETED) NA
  • NCT05778136 — Lung Cancer, Exercise and Force Development (UNKNOWN) NA
  • NCT03266575 — Pulmonary Rehabilitation in End-Stage Liver Disease (TERMINATED) NA
  • NCT05194397 — Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors (RECRUITING) PHASE2
  • NCT05691166 — Reducing Falls With Progressive Resistance Training for the Oldest Old Adults With Sarcopenia (ACTIVE_NOT_RECRUITING) NA
  • NCT06480643 — Effect of Exercise Type on Muscle Quality in Patients With OA, SARC and RA: an Explorative Study (NOT_YET_RECRUITING) NA
  • NCT02873676 — Prevalence and Effect of Lifestyle Modification on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Selenium supplementation OSMF review Supplement Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT05324475 — Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition. (RECRUITING) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation

Natural Products

73 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
Vitamin D3 Natural product Nutraceutical Approved Emerging 19 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 11 Trial pubs
View evidence

Registry trials

  • NCT02402608 — Efficacy of Dietary Supplementation and Physical Activity in Sarcopenic Elderly (COMPLETED) NA
  • NCT02717819 — The Importance of Additional Protein to Benefit More From Training During and After Hospitalization (COMPLETED) NA
  • NCT06791044 — 25(OH)-Vitamin D and Its Association With Structural and Functional Parameters in Hospitalized Patients With Neurological Diseases (RECRUITING) NA
  • NCT00104572 — Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial. (COMPLETED) PHASE2
  • NCT06287502 — Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis (COMPLETED) NA
  • NCT04756856 — Muscle-targeted Nutritional Therapy for the Recovery From COVID-19 (TERMINATED) NA
  • NCT01850251 — Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscle Strength in Hip Fracture (TERMINATED) PHASE4
  • NCT04399291 — Vitamin D Status and Bone Health of Older Adults in Care Facilities (SUSPENDED)

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Omega-3 Fatty Acids Natural product Nutraceutical Phase I Emerging 19 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 2 Cochrane 2 Meta-analysis 6 RCT
View evidence

Registry trials

  • NCT06287502 — Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis (COMPLETED) NA
  • NCT06015971 — Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer (RECRUITING) NA
  • NCT01308957 — Fish Oil and Muscle Function (COMPLETED) NA
  • NCT02374268 — Intervention Assessing the Role of Exercise Program and Nutrition Supplement for Sarcopenia (COMPLETED) NA
  • NCT03598413 — PeRioperative Omega Three and the Effect on ImmuNity (COMPLETED) NA
  • NCT07653737 — Immunonutrition for Prehabilitation of Patients With Colorectal Cancer Before Surgery (COMPLETED) NA
  • NCT06494566 — Omega-3 Supplementation After Surgical Treatment of Obesity (COMPLETED) EARLY_PHASE1
  • NCT05869526 — A Comparison of the Effects of Krill Oil and Fish Oil Supplementation on Muscle Function in Older Adults (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Whey Protein Natural product Nutraceutical Phase II Moderate 19 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials
View evidence

Registry trials

  • NCT02402608 — Efficacy of Dietary Supplementation and Physical Activity in Sarcopenic Elderly (COMPLETED) NA
  • NCT07038655 — Investigating the Digestibility, Bioavailability and Utilisation of Varied Combined Protein Sources in Older Males Using a Dual Stable Isotope Tracer Technique (COMPLETED) NA
  • NCT05700058 — Assessing the Dose-response of Muscle Protein Synthesis to "Super-whey" in Older Adults (RECRUITING) NA
  • NCT02717819 — The Importance of Additional Protein to Benefit More From Training During and After Hospitalization (COMPLETED) NA
  • NCT01986842 — Habitual Protein Intake and Muscle Protein Synthesis (COMPLETED) NA
  • NCT03417531 — Sarcopenia Prevention With a Targeted Exercise and Protein Supplementation Program (COMPLETED) NA
  • NCT04756856 — Muscle-targeted Nutritional Therapy for the Recovery From COVID-19 (TERMINATED) NA
  • NCT01757340 — Calorie Restriction With Leucine Supplementation (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 Examine.com Examine.com
Soy Protein Natural product Nutraceutical Phase II Moderate 19 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 3 Trial pubs
View evidence

Registry trials

  • NCT07038655 — Investigating the Digestibility, Bioavailability and Utilisation of Varied Combined Protein Sources in Older Males Using a Dual Stable Isotope Tracer Technique (COMPLETED) NA
  • NCT04951843 — Koji Product Supplementation' s Study (COMPLETED) NA
  • NCT05869305 — Efficacy and Safety of Protein Product in Volunteers With Sarcopenia (UNKNOWN) NA
  • NCT02529917 — The Benefits of Hemp Protein Supplementation During Resistance Training (COMPLETED) NA
  • NCT01062711 — Dose Response of Whey and Soy Protein Ingestion With and Without Resistance Exercise in Elderly Men (COMPLETED) NA
  • NCT01883674 — Milk and Milk-produce to Counteract the Loss of Muscle Mass and Function in Exercising Older Adults. (COMPLETED) NA
  • NCT01900548 — Effect of Intake of Whey Protein in Elderly Osteopenic Patients. Implications for Metabolism and Physical Function. (COMPLETED) NA
  • NCT05243472 — Impact of Protein-Enriched Lacto-Vegetarian Soup on Muscle Mass and Muscle Strength Among Older Adults (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 Examine.com Examine.com
Iron Natural product Nutraceutical Approved Emerging 16 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
5 trials 3 Trial pubs
View evidence

Registry trials

  • NCT00891696 — Nutritional and Contractile Regulation of Muscle Growth (COMPLETED) PHASE1
  • NCT05485402 — Dietary Strategy to Tackle Sarcopenia in Early Elderly Subjects (FOOP-Sarc) (COMPLETED) NA
  • NCT00690534 — Insulin and Sarcopenia in the Elderly (COMPLETED) PHASE1
  • NCT07162090 — Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients (NOT_YET_RECRUITING) PHASE4
  • NCT05324475 — Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition. (RECRUITING) NA

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Creatine Natural product Amino acid Phase II Emerging 16 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 1 Cochrane 10 Trial pubs
View evidence

Registry trials

  • NCT02062086 — Estimation of Muscle Mass in Older Adults Using Deuterated Creatine (TERMINATED) NA
  • NCT07275996 — Neuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty (ACTIVE_NOT_RECRUITING) NA
  • NCT07463092 — Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy (RECRUITING) NA
  • NCT03530202 — Effects of High-velocity Resistance Training and Creatine Supplementation in Healthy Aging Males (UNKNOWN) PHASE2
  • NCT05008562 — How COVID-19 Effects to Muscle Mass Change ın ICU? (COMPLETED)
  • NCT00473902 — Older Adult Training Study With Creatine and CLA (COMPLETED) NA
  • NCT04058002 — Project Arthritis Recovering Quality of Life Through Education 70+ (UNKNOWN) NA
  • NCT07625202 — Creatine Supplementation During GLP-1a Therapy (RECRUITING) NA

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Medium-Chain Triglycerides Natural product Nutraceutical Phase I Moderate 13 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT06376266 — Assessment of the Intervention Effectiveness of Branched-chain Amino Acids(BCAA) Combined With Medium-chain Fatty Acid(MCFA) Products in Sarcopenia Among Middle-aged and Elderly Individuals (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 Examine.com Examine.com
Vitamin D3 Natural product Nutraceutical Approved Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 11 Trial pubs
View evidence

Registry trials

  • NCT02402608 — Efficacy of Dietary Supplementation and Physical Activity in Sarcopenic Elderly (COMPLETED) NA
  • NCT02717819 — The Importance of Additional Protein to Benefit More From Training During and After Hospitalization (COMPLETED) NA
  • NCT06791044 — 25(OH)-Vitamin D and Its Association With Structural and Functional Parameters in Hospitalized Patients With Neurological Diseases (RECRUITING) NA
  • NCT00104572 — Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial. (COMPLETED) PHASE2
  • NCT06287502 — Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis (COMPLETED) NA
  • NCT04756856 — Muscle-targeted Nutritional Therapy for the Recovery From COVID-19 (TERMINATED) NA
  • NCT01850251 — Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscle Strength in Hip Fracture (TERMINATED) PHASE4
  • NCT04399291 — Vitamin D Status and Bone Health of Older Adults in Care Facilities (SUSPENDED)

CT.gov search · Cochrane · PubMed

 PubChem
Omega-3 Fatty Acids Natural product Nutraceutical Phase I Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 2 Cochrane 2 Meta-analysis 6 RCT
View evidence

Registry trials

  • NCT06287502 — Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis (COMPLETED) NA
  • NCT06015971 — Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer (RECRUITING) NA
  • NCT01308957 — Fish Oil and Muscle Function (COMPLETED) NA
  • NCT02374268 — Intervention Assessing the Role of Exercise Program and Nutrition Supplement for Sarcopenia (COMPLETED) NA
  • NCT03598413 — PeRioperative Omega Three and the Effect on ImmuNity (COMPLETED) NA
  • NCT07653737 — Immunonutrition for Prehabilitation of Patients With Colorectal Cancer Before Surgery (COMPLETED) NA
  • NCT06494566 — Omega-3 Supplementation After Surgical Treatment of Obesity (COMPLETED) EARLY_PHASE1
  • NCT05869526 — A Comparison of the Effects of Krill Oil and Fish Oil Supplementation on Muscle Function in Older Adults (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 PubChem
Magnesium Natural product Nutraceutical Approved Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 3 Cochrane 3 Meta-analysis 4 Trial pubs 4 RCT
View evidence

Registry trials

  • NCT07567963 — Magnesium Supplementation as a Nutritional Intervention in Sarcopenia (NOT_YET_RECRUITING) NA
  • NCT05348694 — OsteoPreP: Food Supplements for Postmenopausal Bone Health (UNKNOWN) PHASE4
  • NCT06851676 — Functional and Metabolic Effects of Fonte Fausta® Water on Bone and Muscle Health in Osteoporotic Patients (RECRUITING) NA
  • NCT01775111 — Influence of Strength Training and Protein Supplementation on Fitness of Institutionalized Elderly (UNKNOWN) NA
  • NCT05872360 — To Investigate Effects of Amway Bundle Combination of Products on Osteoarthritis & Sarcopenia (COMPLETED) NA
  • NCT04354896 — The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism (COMPLETED) PHASE4
  • NCT05730985 — From the Gut to the Strut: Reducing Inflammation for Healthy Muscles (UNKNOWN) NA
  • NCT06248437 — Prototype of Innovative Food Product to Improve Respiratory and Peripheral Muscle Function in Humans (COMPLETED)

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Vitamin B12 Natural product Nutraceutical Preclinical Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
3 trials 1 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT01775111 — Influence of Strength Training and Protein Supplementation on Fitness of Institutionalized Elderly (UNKNOWN) NA
  • NCT05324475 — Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition. (RECRUITING) NA
  • NCT06248437 — Prototype of Innovative Food Product to Improve Respiratory and Peripheral Muscle Function in Humans (COMPLETED)

CT.gov search · Cochrane · PubMed

 PubChem
N-Acetylcysteine Natural product Amino acid Preclinical Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 Cochrane
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Taurine Natural product Amino acid Preclinical Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials
View evidence

Registry trials

  • NCT05415176 — Taurine Supplementation Associated or Not With Exercise: Effect on Browning of White Adipose Tissue in Elderly Women With Sarcopenic Obesity (UNKNOWN) NA
  • NCT04516421 — Protein Supplementation Intervention for Improving Muscle Mass and Physical Performance in Older People With Sarcopenia (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 PubChem
Nicotinamide Mononucleotide Natural product Food compound Preclinical Moderate 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Curcumin Natural product Food compound Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 Cochrane 2 Trial pubs
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
L-Citrulline Natural product Amino acid Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT03694964 — Severe Chronic Respiratory Failure and Citrulline (UNKNOWN) NA
  • NCT02417428 — Citrulline Supplementation Combined With Exercise: Effect on Muscle Function in Elderly People (CITEX Study) (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Resveratrol Natural product Food compound Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
3 trials
View evidence

Registry trials

  • NCT06585865 — Strength Training and Resveratrol (RECRUITING) NA
  • NCT05981053 — Biological Effects in Consumers of Resveratrol-enriched Wine (COMPLETED)
  • NCT02001831 — Multi-ingredient Nutrition Supplement in Older Adults (UNKNOWN) NA

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Ginseng Natural product Botanical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials 1 RCT
View evidence

Registry trials

  • NCT05919368 — The Shape Regulation Mechanism of Yam Pill on Patients With Sarcopenia Based on Intestine-muscle-brain Axis (UNKNOWN) NA

Published literature

CT.gov search · Cochrane · PubMed

 —
Creatine Natural product Amino acid Phase II Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 1 Cochrane 10 Trial pubs
View evidence

Registry trials

  • NCT02062086 — Estimation of Muscle Mass in Older Adults Using Deuterated Creatine (TERMINATED) NA
  • NCT07275996 — Neuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty (ACTIVE_NOT_RECRUITING) NA
  • NCT07463092 — Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy (RECRUITING) NA
  • NCT03530202 — Effects of High-velocity Resistance Training and Creatine Supplementation in Healthy Aging Males (UNKNOWN) PHASE2
  • NCT05008562 — How COVID-19 Effects to Muscle Mass Change ın ICU? (COMPLETED)
  • NCT00473902 — Older Adult Training Study With Creatine and CLA (COMPLETED) NA
  • NCT04058002 — Project Arthritis Recovering Quality of Life Through Education 70+ (UNKNOWN) NA
  • NCT07625202 — Creatine Supplementation During GLP-1a Therapy (RECRUITING) NA

CT.gov search · Cochrane · PubMed

 PubChem
Berberine Natural product Botanical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 PubChem
Sulforaphane Natural product Food compound Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Spirulina Natural product Nutraceutical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Chamomile Natural product Botanical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Fenugreek Natural product Botanical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Ginkgo Biloba Natural product Botanical Preclinical Emerging 2 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Manzamine a Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ChEMBL ChEMBL PubChem ChEMBL
Nifedipine Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ChEMBL ChEMBL PubChem ChEMBL
Nimodipine Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ChEMBL ChEMBL PubChem ChEMBL
1H-indol-3-ylmethyl(dimethyl)amine Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ChEMBL ChEMBL PubChem ChEMBL
Nicotinamide Mononucleotide Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]pyridin-1-ium-3-carboxamide Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ClinicalTrials.gov PubChem
(2S)-2-amino-4-methyl-valeric acid Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ClinicalTrials.gov PubChem
(7-chloro-4-hydroxy-5-phenyl-3H-1,4-benzodiazepin-2-ylidene)-methyl-amine Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ClinicalTrials.gov PubChem
3-hydroxy-3-methyl-butyric acid Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ClinicalTrials.gov PubChem
Whey Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Ginseng (Korean) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Ginsenosides Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Lactobacillus Plantarum Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Polyphenols Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Rutin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Icariin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Goji Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Puerarin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Nuts: All Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Leucine Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Miso Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Krill Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Olive Leaf Extract Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Chlorella (Algae) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Beta Sitosterol Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Blue Honeysuckle Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Baicalein Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Betaine Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Propolis: Brazillian Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
CLA (Conjugated Linoleic Acid) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Emodin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Ginseng (American) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Hesperidin Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Lactobacillus Paracasei Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Loquat Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Psilocybin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Luteolin Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Oligonol Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Lactoferrin Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
GABA (Gamma-Aminobutyric Acid) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Butyrate Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Astaxanthin Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Carotenoids Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Royal Jelly Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Propolis: Bee Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Formononetin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Burdock Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Flavonoids Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Generated by OSMF Disease Intelligence Pipeline · Schema 1.1.0